This scientific commentary refers to 'Retinal inner nuclear layer volume reflects response to immunotherapy in multiple sclerosis', by Knier et al. (doi:10 .1093/brain/aww219).
A recent article in Brain by Gelfand et al. (2012) on the inner nuclear layer (INL) of the retina in multiple sclerosis triggered a lively exchange of Letters to the Editor. With the advent of optical coherence tomography (OCT), a forgotten autopsy observation was restored to the top of the research agenda in multiple sclerosis. Over 150 years ago, severe atrophy of the retinal nerve fibre layer (RNFL) and ganglion cell layer (GCL) was shown to be associated with only subtle changes in the INL whilst the outer retinal layers were completely preserved (Mü ller, 1857) . Although Heinrich Mü ller was cautious in interpreting potential INL changes, he was more convinced about the existence of secondary (retrograde) axonal degeneration. 'Die sogenannten Kö rner erschienen etwas kö rnig, doch war mir sehr zweifelhaft, ob dies als pathologische Verä nderung anzusprechen sei, da man Aehnliches auch sonst zu Gesicht bekommt.' This case was discussed on pages 92-98 and the citation taken from page 93 (Mü ller, 1857) . For the contemporary translation it is important to refer back to the terminology of the time. There were three 'Kö rnerschichten' that correspond to the present day: 'ganglion cell layer', 'inner nuclear layer' and 'outer nuclear layer'.
Mü ller was not able to see the GCL and his comment is on the next nuclear layer, the INL: 'The so called nuclei seemed more grainy, but I am rather doubtful if this should be interpreted as a (specific) pathological finding as one can see similar features in other situations'.
Subsequent histological studies of the macaque monkey eye following experimental lesions to the afferent visual pathway provided evidence for retrograde trans-synaptic degeneration reaching the GCL with associated changes in the INL (van Buren, 1963) . Lesions of the optic chiasm led to thinning of the RNFL and GCL and to formation of cystic spaces in the INL, which 'were irregularly rounded [the larger of which] contained fine strands of tissue and debris'. Occipital cortex lesions, by contrast, did not affect the INL or any of the outer retinal layers (van Buren, 1963) . INL changes following optic nerve or chiasm lesions are the likely histological equivalent of what has been called 'microcystic macular oedema' (MMO) . I will later return to the debate surrounding MMO in an attempt to explain the next relevant observation, the frequent increase in INL thickness in multiple sclerosis patients in the absence of obvious MMO. Increased thickening of the pooled outer plexiform and INLs was found to be associated with signs of inflammation in multiple sclerosis (Saidha et al., 2012) . Together these studies raised the possibility that MMO and INL thickening might be comparable to an MRI 'T 2 lesion' and could be useful as a surrogate outcome for treatment trials in multiple sclerosis (Petzold, 2012) . In this issue of Brain, Knier et al. report that effective diseasemodifying treatment in patients with multiple sclerosis is associated with volume reduction of the INL (Knier et al., 2016) .
Recruitment for the present study started at the time of publication of the two landmark papers that reported a positive correlation between INL thickness and multiple sclerosis disease activity Saidha et al., 2012) . Three years later 121 patients suffering from relapsing-remitting multiple sclerosis and 40 healthy control subjects had been enrolled. Patients were grouped into those who had received no disease-modifying therapy (no DMT, n = 36), a first line drug (1st DMT, n = 47) or a second line drug (2nd DMT, n = 25). Not surprisingly the latter subgroup consisted of patients who had significantly more disease activity based on clinical and radiological criteria.
A potential confound is multiple sclerosis-associated optic neuritis (MSON), which occurs at some stage in $80% of patients with multiple sclerosis. Such patients have more severe damage to the inner retinal layers and are more likely to show MMO. A frequent criticism of OCT studies is the potential bias caused by inclusion of MSON. In fact, in the disease activity could not be controlled. So is INL volume reduction a response marker for successful treatment of inflammation in multiple sclerosis?
As mentioned above, the discovery of MMO and volume changes of the INL prompted an extensive correspondence in Brain. Abegg et al. (2012) pointed out that MMO may be caused by retrograde axonal degeneration as a result of any type of lesion in the anterior optic pathways, and proposed the term 'retrograde maculopathy' to describe this phenomenon. At the same time we (Balk et al., 2012) also showed that MMO was not specific to multiple sclerosis, and suggested that an impaired capacity of Mü ller cells to maintain retinal fluid homoeostasis might be relevant. The Mü ller cell hypothesis is consistent with the finding that the INL volume can be reduced by acetazolamide, which improves the water-pumping function of Mü ller cells (Abegg, 2016) . However, it has also been suggested that MMO results from neither inflammatory nor trans-synaptic degeneration (Barboni et al., 2013 ). An alternative hypothesis implicates traction at the vitreoretinal interface (Petzold, 2012; Lujan and Horton, 2013) . Among observations that call for explanation is that MMO is transient in 84% of cases studied longitudinally (Burggraaff et al., 2014) .
In summary, the Knier et al. study takes the discovery of MMO and INL volume changes Saidha et al., 2012) to the next level. But because it is essentially correlative, it further emphasizes the need for a comprehensive understanding of the underlying mechanisms in the retina. Taken together, the observations imply that dynamic fluid shifts, likely related to inflammation, vascular permeability and Mü ller cell function, need to be considered, as well as non-inflammation related changes such as traction and a retrograde maculopathy. The location of MMO suggests a close relationship to Mü ller cells and the retinal vasculature (Balk et al., 2012) . Mü ller cell somata reside in the INL and their processes encompass the capillary plexus of the retina (Fig. 1) . Above the INL lies the superficial vascular plexus; below the INL lies the deep capillary plexus. Both are readily visualized by OCT angiography and are connected vertically by small vessels. Understanding fluid trafficking through the retina and Mü ller cells will now be important to better explain volume changes of the INL: Fig. 1 summarizes the potential mechanisms involved.
Borrowing from the introductory allegory of a 'T 2 lesion' for INL oedema, an increase of volume from normal (Fig. 1A) could be caused by extra-and/or intracellular fluid accumulation ( Fig. 1B and C) . Mü ller cells were proposed to play a central role in this process (Balk et al., 2012) . Mü ller cells manage retinal fluid homeostasis by water and ion buffering. Therefore, Mü ller cells express water and ion channels. The aquaporin 4 (AQP4) and potassium (Kir 4.1) channels expressed on Mü ller cells have been shown to be a target of autoimmune disease (Petzold et al., 2016) . There is new evidence for loss of AQP4 on Mü ller cell sidebranches following experimental transfer of AQP4-specific T cells (Zeka et al., 2016) . Moving from the retina to the brain, the glial water channel AQP4, located in the astrocytic perivascular endfeet, facilitates water movement in the CNS. Conventional understanding is that AQP4 governs the rate of osmotic astrocytic volume change in the brain. Osmotic pressure gradients were understood to be more relevant than hydrostatic pressure gradients. More recently the 'glymphatic' hypothesis of the brain proposed that hydrostatic pressure also determines trans-astrocytic water flow through AQP4 channels with blood vessel pulsation as an important contributing factor (Iliff et al., 2012) . There is a considerable degree of variation of brain interstitial space with physiological/diurnal changes of flow through the brain glymphatic system. Moving back from the brain to the retina, it is Glossary Glymphatic system: Originally described for the brain, a paravascular pathway for CSF and interstitial fluid (ISF) exchange. The brain glymphatic system contributes to physiological clearance of compounds from the ISF of the CNS, and is particularly important for clearance of proteins related to neurodegeneration. The glymphatic system has similarities with the lymphatic system. The relevance of glial cells is reflected in the name 'g'lymphatic. The existence of a retinal glymphatic system has not yet been shown experimentally. Optical coherence tomography (OCT): A non-invasive, very fast method that permits construction of an image based on the amount of light reflected (back scattered) from tissue. The axial resolution of current spectral domain OCT devices is 3-7 mm. For comparison the thickness of a retinal ganglion cell is 5-20 mm. OCT therefore permits in vivo research on a cellular level. Trans-synaptic axonal degeneration: A key concept underlying OCT research in multiple sclerosis. Trans-synaptic axonal degeneration explains why it is possible to measure atrophy of INLs with OCT in patients with multiple sclerosis, with or without MSON. Any lesion in a hard wired pathway, such as the projection from the retinal ganglion cell to the primary visual cortex will result in axonal degeneration. The direction of axonal degeneration is described as anterograde (or Wallerian) if it moves away from its neuron and retrograde if it moves towards its neuron. A key question that remains to be answered is why degeneration moves on to the next, supposedly 'healthy' neuron. In a 'domino effect' all neurons in the hard wired visual pathway eventually succumb to neurodegeneration, including first order neurons in the retinal GCL, second order neurons in the dorsal lateral geniculate nucleus and third order neurons in the primary visual cortex. In the strict definition of this single pathway model, absent excitatory input from presynaptic cells might be an attractive hypothesis. Alternatively one might think of 'nexopathies' and transport of 'toxic'/ damaged proteins or aggregates. From a therapeutic point of view targeting trans-synaptic axonal degeneration will likely be more promising than trying to cure axonotmesis. therefore instructive to note that hyperaemia but not hydration is relevant to a transient, physiological change of retinal layer thicknesses (Balk et al., 2013 . In disease, with two notable exceptions, traction and trans-synaptic axonal degeneration (Fig. 1D) , INL volume changes might therefore be explained by extending the glymphatic hypothesis from the brain to the retina. This concept might appeal to both the neurological and ophthalmological communities as findings are likely to encompass a broad disease spectrum (Mü ller, 1857; Balk et al., 2012; Burggraaff et al., 2014) .
To conclude, patient numbers in the exciting longitudinal data presented by Knier et al. were small, but this throws down the gauntlet to everyone who can get their hands on existing multiple sclerosis OCT trial data. Can reduction of INL volume be validated as a biomarker for sustained control of CNS inflammation by therapeutic interventions? Publication of both positive and negative data will be highly informative for answering this question. Cerebral small vessel diseases refer to pathological processes that affect the structure or function of small vessels of the brain, including arteries, arterioles, capillaries, and occasionally venules (Pantoni, 2010) . While the majority of small vessel diseases are sporadic age-related conditions driven by a complex interaction between genetic and cardiovascular risk factors or cerebrovascular amyloid deposition, inherited (familial) cerebral small vessel diseases have been increasingly reported in recent years (Joutel and Faraci, 2014) . Of these inherited diseases, CADASIL (cerebral autosomal dominant arteriopathy with subcortical infarcts and
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